Topical vs. Oral Finasteride: The Systemic Absorption Data Compared

Topical finasteride suppresses scalp DHT with roughly 20–30% systemic reduction versus oral's 65–70%. That difference is real and the reason many men choose topical — but the trade-offs are worth understanding clearly.

The fundamental trade-off in oral versus topical finasteride is systemic exposure. Both achieve scalp DHT suppression; they differ significantly in how much systemic DHT they reduce. That difference is the reason topical exists as an option.

The serum DHT comparison

Oral finasteride 1mg daily: reduces serum DHT by approximately 65–70% at steady state. Well-documented across large trials.

Topical finasteride (optimised formulations): serum DHT reduction in published studies ranges from approximately 7–32%, depending on formulation, vehicle, concentration, and application method. A frequently cited 0.25% topical solution achieves approximately 20–30% serum DHT suppression.

The gap — 20–30% versus 65–70% — is the core of the topical argument. Systemic androgen modulation is substantially less from topical, which is hypothetically relevant for side effects driven by systemic DHT reduction.

Scalp DHT: where it actually counts

Well-formulated topical finasteride achieves scalp DHT reductions in a similar range to oral — approximately 60–70% in studies using scalp biopsy methodology. The vehicle matters substantially: formulations designed for follicular penetration outperform simple solutions on local concentration. Not all compounded topicals are equal.

The implication: similar scalp DHT suppression with considerably lower systemic exposure. That is the theoretical basis for topical working as well for hair while causing fewer systemic side effects.

The side effect question

The most discussed finasteride side effects — reduced libido, erectile dysfunction, ejaculatory changes — are hypothesised to relate to systemic DHT suppression. Lower serum DHT from topical should produce fewer of these effects if the hypothesis is correct. Available small comparative studies are consistent with fewer sexual side effects for topical; larger definitive trials are lacking. The rationale is sound; clinical confirmation is incomplete.

What you give up with topical

The oral evidence base is substantially larger. The pivotal AGA trials used oral finasteride; the clinical data on hair outcomes is extensive. Topical has a smaller evidence base and more formulation variability — compounding quality matters and varies between pharmacies. The prescribing platform and pharmacy source matter when choosing topical in a way they do not for commercial oral tablets.

The decision

For men with no specific concerns about oral's systemic profile: oral is reasonable first-line given the larger evidence base. For men who have experienced or are concerned about systemic side effects: topical has a well-founded rationale. Either is a defensible choice with an informed clinician involved.